Biocytogen Pharmaceuticals Co. Ltd. subsidiary Eucure Biopharma Co. Ltd. has formed a partnership with Syncromune Inc. to combine Eucure’s YH-002 and two other active ingredients with Syncromune’s Syncrovax platform technology.
Inxmed Co. Ltd. has formed a partnership with Shanghai Huaota Biopharmaceutical Co. Ltd. to combine the former’s IN-10018 and the latter’s HB-0030 for the treatment of solid tumors by jointly running preclinical studies and clinical trials.
Sumitovant Biopharma Ltd., a subsidiary of Sumitomo Pharma Co. Ltd., agreed to acquire Myovant Sciences Ltd. for $27 per share, up from its earlier offer of $22.75 per share, which Myovant had rebuffed. The deal is worth $1.7 billion on a fully diluted basis, with an equity value of about $2.59 billion.
Celltrion Healthcare Inc. has signed a deal with Pinotbio Inc. to develop antibody-drug conjugates for up to 15 separate cancer targets incorporating the linker-payload platform technology Pinot-ADC. Celltrion could pay Pinotbio as much as ₩1.77 trillion (US$1.24 billion) to exercise options for all 15 targets in the collaboration. But, for starters, it will pay Pinotbio ₩1 billion up front.
Aural Analytics Inc. and Hhitt Inc., dba Hitcheck, teamed up to offer a cognitive assessment application that could quickly answer the question, “Should he play?” after a hit to the head during a game. Considering the controversy over Miami Dolphins quarterback Tua Tagovailoa’s loss of consciousness following his second head injury in two games last month, the cognitive assessment tool, which includes clinical-grade speech analytics, comes none too soon.
Inxmed Co. Ltd. has formed a partnership with Shanghai Huaota Biopharmaceutical Co. Ltd. to combine the former’s IN-10018 and the latter’s HB-0030 for the treatment of solid tumors by jointly running preclinical studies and clinical trials.
In its first oncology licensing collaboration, Hookipa Pharma Inc. is partnering with Roche Holding AG to develop an arenaviral for treating KRAS-mutated cancers. Roche will pay $25 million up front to Hookipa, which could ultimately bring in about $930 million in milestone-based payments as part of the deal.
U.K.-based seed investor Lifearc Ventures is celebrating a second major deal from its portfolio of companies after Abbvie Inc. bought the tiny former “garage startup" DJS Antibodies Ltd. for $255 million up front plus undisclosed milestone payments. DJS’ lead program is DJS-002, a potential first-in-class lysophosphatidic acid receptor 1 antagonist in preclinical studies for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases.
The value of med-tech mergers and acquisitions, as well as deals, fell in the third quarter, although 2022 remains a standout year. M&As are at a five-year high, while deals are second only to 2019, in terms of overall value during the first three quarters. The volume of M&As are behind 2021, but deal volume this year remains on top.
Biocytogen Pharmaceuticals Co. Ltd. subsidiary Eucure Biopharma Co. Ltd. has formed a partnership with Syncromune Inc. to combine Eucure’s YH-002 and two other active ingredients with Syncromune’s Syncrovax platform technology in a deal the partners said could be worth “hundreds of millions of U.S. dollars,” including an up-front cash payment of undisclosed value.
RSS
